| Original language | English |
|---|---|
| Pages (from-to) | 230-233.e3 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 134 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2014 |
Bibliographical note
Funding Information:The authors acknowledge financial support for this study from a “Kamin” grant of the Israel Ministry of Industry and Trade (Grant no. 46223) and The Aimwell Charitable Trust Foundation (UK) to F.L.-S.; European Cooperation in Science and Technology COST Action BM1007 “Mast Cells and Basophils - Targets for Innovative Therapies” facilitated the collaboration between F.L.-S. and B.F.G. in support of this study. F.L.-S. is a member of the Dr Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy.
Funding Information:
Disclosure of potential conflict of interest: S. Mizrahi has received travel support from the European Cooperation in Science and Technology COST Action BM1007. B. F. Gibbs has received start-up funds from and is employed by the University of Kent, has received payment for lectures from the University of Virgina and ALK Abello, and has received travel support from EU/ESF COST Action BM1007. F. Levi-Schaffer has received research support from the Israeli Ministry of Industry and Trade (Grant No. 46223); is a member of the Committee for Human Experimentation of New Drugs for the Israeli Ministry of Health; and has received travel support from EU/ESF COST Action BM1007. The rest of the authors declare that they have no relevant conflicts of interest.
